South Rampart Pharma Expands Global Patent Portfolio with EU Approval for FDA Fast-Tracked SRP-001 for Pain
November 1, 2023 South Rampart’s Global Intellectual Property Portfolio Now
South Rampart Pharma Receives U.S. FDA Fast Track Designation for SRP-001 for Acute Pain
Oct. 12, 2023 The Fast Track designation accelerates SRP-001's path
South Rampart Pharma to Participate in Upcoming Investor Events
October 10, 2023 - BIO Investor Forum taking place on
South Rampart Pharma Awarded Second NIH Grant for Commercialization Readiness Pilot Program
Sept. 21, 2023 The NIH's CRP Award Further Validates the
South Rampart Pharma Announces First Patient Enrolled in Multiple Ascending Dose Portion of Ongoing Phase 1 ClinicalTrial
August 22, 2023 - SRP-001, a novel, non-opioid investigational drug
South Rampart Pharma Further Expands Patent Portfolio for SRP-001 with Composition of Matter Patent in China
July 6, 2023 South Rampart's global intellectual property portfolio now
South Rampart Pharma to Present at 2023 BIO CEO & Investor Conference
Jan. 31, 2023 Hernan Bazan, MD, FACS, CEO and Co-Founder,
South Rampart Pharma Announces Presentation at Arrowhead’s 16th Annual Pain Therapeutics Summit
Oct. 21, 2022 South Rampart Pharma ("South Rampart" or the
South Rampart Pharma Issued Composition of Matter Patent for Novel Non-Toxic Treatment for Pain
Oct. 4, 2022 - New patent grant further secures South Rampart's
South Rampart Pharma Receives Year 3 of NIH Fast-Track STTR Commercialization Grant
Sept. 22, 2022 South Rampart Pharma ("South Rampart" or the